Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 82 Equity-to-Asset is 0.28 as of Mar. 2026, which is 4% above its 10-year median of 0.27. GuruFocus rates SARTF with a GF Score™ of 82/100 and a GF Value™ of $274.11 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Sartorius AG ranks worse than 85.7% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sartorius AG's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $3,152 Mil. Sartorius AG's Total Assets for the quarter that ended in Mar. 2026 was $11,413 Mil.
Therefore, Sartorius AG's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.28.
The historical rank and industry rank for Sartorius AG's Equity-to-Asset or its related term are showing as below:
SARTF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21 Med: 0.27 Max: 0.33
Current: 0.28
During the past 13 years, the highest Equity to Asset Ratio of Sartorius AG was 0.33. The lowest was 0.21. And the median was 0.27.
SARTF's Equity-to-Asset is ranked worse than 85.7% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs SARTF: 0.28
Sartorius AG (OTCPK:SARTF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sartorius AG Equity-to-Asset Related Terms
Sartorius AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sartorius AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a Equity-to-Asset of 0.28 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sartorius AG and its competitors. This is near median its historical median of 0.27. Over the past decade, Sartorius AG's Equity-to-Asset has ranged from 0.21 to 0.33. According to the industry distribution chart, Sartorius AG ranks #731 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 85.7%.
Is Sartorius AG's Equity-to-Asset too high?
Sartorius AG's current Equity-to-Asset of 0.28 is near median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 0.33. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Sartorius AG's value of 0.28 is 56.9% below this industry median. Based on the distribution chart, Sartorius AG ranks #731 out of 853 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #731 out of 853 companies for Equity-to-Asset. This places Sartorius AG in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Sartorius AG's value of 0.28 is 56.9% below this benchmark. Historically, Sartorius AG's own Equity-to-Asset has ranged from 0.21 to 0.33 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 0.65, Sartorius AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Equity-to-Asset of 0.28 is 56.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Equity-to-Asset is 0.28, which is near median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $274.11, compared to a current price of $212.80 — trading 22.4% below its estimated fair value. The current Equity-to-Asset is 0.28, which is near median its 10-year median of 0.27 and 56.9% below the Medical Devices & Instruments industry median of 0.65. Sartorius AG's overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Equity-to-Asset is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.4% below its estimated GF Value™ of $274.11.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Equity-to-Asset: 0.28 (near median its 10-year median of 0.27)
GF Value™: $274.11 vs. price of $212.80 (22.4% below fair value)
Industry Position: 56.9% below the Medical Devices & Instruments median (#731 of 853)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
82GF Score
Get the complete analysis for SARTF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
